• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Scientific articles
2026-11-16

An AI-powered smartphone application for universal and standardized reading and interpretation of lateral flow assays

PLOS Global Public Health

by Bermejo-Peláez D, Darias O, Pastor L, Vallés R, Diez N, Lin L, García-Villena J, Cuadrado D, Vladimirov A, Álamo E, Postigo M, Rodriguez-Dominguez M, Cantón R, Rodriguez-Tudela JL, Alastruey Izquierdo A, Marchiol A, Segura Alba ML, Cortés Cortés LJ, Bohorquez LC, Rubio JM, Dacal E, Luengo-Oroz M. PLOS Global Public Health 2026, 6(11):e0005817. doi:10.1371/journal.pgph.0005817

Summary: Lateral flow assays (LFAs) are indispensable rapid diagnostic tools, however, misinterpretation errors and unreported cases are a concern. The authors of this manuscript describe a universal AI model to digitize and interpret results from multiple LFA types through a smartphone application. The algorithm was evaluated in 17 LFA types for different diseases and manufacturers, and trained on 22,576 images captured under diverse lighting conditions with different smartphone models. The model achieved an overall AUC of 95.3% for second band detection of LFA types not previously analyzed, which was enhanced to 99.4% after training with 50 images of each LFA type. This demonstrates the feasibility of an AI-powered universal reader for interpreting LFA results from diverse test types using smartphone-captured images

Access article

AI & New Tech Chagas disease Malaria Pandemic preparedness and response

Latest scientific articles

Loading...
Scientific articles
3 Nov 2026

Transcriptomic and proteomic analysis of quiescent epimastigotes as a resource for investigating Trypanosoma cruzi persistence

Communications Biology
Scientific articles
27 Oct 2026

Strengthening health systems and clinical development capacities through effective partnerships: a case study of DNDi’s collaboration with the Leishmaniasis Research and Treatment Center in Ethiopia (2003–2022)

Frontiers in Tropical Diseases
Scientific articles
26 Oct 2026

Efficacy and safety of oxfendazole in adults with Trichuris spp. infection in Pemba Island, Tanzania: a double-blind, phase 2a, randomised controlled trial

eClinicalMedicine
Scientific articles
22 Oct 2026

Deconvoluting the mode of action of antileishmanial aminopyrazoles through chemical mutagenesis

Nature communications
VIEW ALL

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license